CTC Pancreatic Adenocarcinoma

Health conditions (Data source: WHO)

Adenocarcinoma;Circulating Tumor Cells;Pancreatic Neoplasms

Interventions (Data source: WHO)

Drug: Desflurane

Inclusion/Exclusion Criteria (Data source: WHO)

Inclusion Criteria:

- Age 18 to 85

- ASA I-III ( American Society of Anesthesiologists)

- Resectable pancreatic adenocarcinoma

- Primary surgery

- No neoadjuvant therapy

- Written informed consent

Exclusion Criteria:

- Metastatic disease

- Other than primary surgery (recurrence, reconstruction)

- Pre-operative chemotherapy

- Chronic opioid use

- Known hypersensitivity or suspected allergy to propofol, soya or egg proteins

- Known hypersensitivity to volatile anaesthetics (malignant hyperthermia)

- Pregnancy

- Breast feeding

- Enrolment in any other clinical trial during the course of this trial, 30 days prior
to its beginning or 30 days after its completion

Further information on the trial in WHO primary registry

https://clinicaltrials.gov/show/NCT02335151

Further information on the trial from WHO database (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=NCT02335151

Further information on trial

Date trial registered

Dec 13, 2014

Incorporation of the first participant

Oct 1, 2016

Recruitment status

Completed

Academic title (Data source: WHO)

Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?

Type of trial (Data source: WHO)

Interventional

Design of the trial (Data source: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).

Phase (Data source: WHO)

Phase 4

Primary end point (Data source: WHO)

Peak of CTC in the postoperative phase after curative tumor removal

Secundary end point (Data source: WHO)

Number of surviving patients;Month to Tumor recurrence;Kinetics of CTC after surgery up to day 7

Contact information (Data source: WHO)

Please refer to primary and secondary sponsors

Trial results (Data source: WHO)

Results summary

no information available yet

Link to the results in the primary register

no information available yet

Information on the availability of individual participant data

No
Data will not be shared

Trial sites

Countries (Data source: WHO)

Switzerland

Contact for further information on the trial

Contact for general information (Data source: WHO)

Beatrice Beck Schimmer, Prof. MD
University of Zurich

Contact for scientific information (Data source: WHO)